8-K: CytoSorbents Reports Q3 2024 Results: Revenue Growth and Regulatory Progress

CytoSorbents announced an 11% increase in product revenue for Q3 2024, alongside key regulatory milestones for DrugSorb-ATR.

Summary

• CytoSorbents reported a product revenue of $8.6 million for the third quarter of 2024, an 11% increase compared to $7.8 million in the same period last year.
• Total revenue, including product and grant revenue, reached $9.4 million, a 7% increase from $8.8 million in Q3 2023.
• The company experienced a decrease in product gross margins to 61%, down from 72% in Q3 2023, due to a planned production slowdown and a short-term manufacturing issue.
• Net loss for the quarter was $2.3 million, or $0.04 per share, an improvement from a net loss of $9.2 million, or $0.21 per share, in Q3 2023.
• Adjusted net loss improved to $4.5 million, or $0.08 per share, compared to an adjusted net loss of $6.0 million, or $0.14 per share, in Q3 2023.
• Adjusted EBITDA loss improved to $3.6 million, compared to a loss of $5.6 million in Q3 2023.
• Total cash, including cash equivalents and restricted cash, was $12.2 million, down from $14.9 million at the end of Q2 2024, but cash used in the quarter improved by $2.7 million compared to $5.0 million used in Q2 2024.
• The company submitted its DrugSorb-ATR De Novo application to the U.S. FDA on September 27, 2024, and received acceptance and initiation of substantive review on October 22, 2024.
• CytoSorbents received Medical Device Single Audit Program (MDSAP) certification on November 1, 2024, and submitted its Medical Device License (MDL) application to Health Canada on the same day.
• The potential North American DrugSorb-ATR total addressable market (TAM) in patients undergoing CABG surgery on Brilinta is estimated to exceed $300 million, with potential to grow to $1-2 billion with label expansion.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the revenue growth, improved net loss, and regulatory progress. However, the decrease in gross margins and cash reserves are areas of concern, preventing a higher score.

Positives

• The company achieved an 11% increase in product revenue year-over-year.
• Total revenue also saw a 7% increase compared to the same quarter last year.
• Net loss significantly improved from $9.2 million to $2.3 million year-over-year.
• Adjusted EBITDA loss also improved, indicating better cost management.
• The company successfully submitted its DrugSorb-ATR application to the FDA and received acceptance for review.
• MDSAP certification was obtained, streamlining regulatory compliance in multiple key markets.
• The company is nearing cash flow breakeven with its core international CytoSorb business.
• The company is seeing enthusiasm for its new PuriFi hemoperfusion pump.

Negatives

• Product gross margins decreased to 61% from 72% in the same quarter last year due to production issues.
• Total cash decreased from $14.9 million at the end of Q2 2024 to $12.2 million at the end of Q3 2024.
• The company still reported a net loss of $2.3 million for the quarter.

Risks

• The company experienced a decrease in product gross margins due to a planned production slowdown and a short-term manufacturing issue.
• The company's cash reserves decreased during the quarter.
• The company is still operating at a loss, although the loss has improved.
• The regulatory approval of DrugSorb-ATR is not guaranteed and is subject to FDA and Health Canada review.
• The company's future success is dependent on the commercial launch and market adoption of DrugSorb-ATR.

Future Outlook

The company anticipates a return to more normalized production levels and product gross margins in the fourth quarter of 2024. They are also preparing for the potential commercial launch of DrugSorb-ATR in North America, pending regulatory approvals.

Management Comments

• Dr. Phillip Chan, Chief Executive Officer, stated that he is pleased with the progress made this quarter.
• Dr. Chan noted that the company's topline performance is a testament to the improving strength of their critical care and cardiac surgery businesses.
• Dr. Chan mentioned that manufacturing is now running smoothly with an expected return to more normalized production levels and product gross margins in the fourth quarter of this year.
• Dr. Chan believes that the company has significantly improved its operating metrics and continues to demonstrate a disciplined approach to cash management.
• Dr. Chan stated that the potential expansion of their markets to the U.S. and Canada with DrugSorb-ATR could be game-changing.
• Dr. Chan is confident that DrugSorb-ATR has the ability to transform the current standard of care in patients with acute coronary syndromes.

Industry Context

This announcement comes as the company is seeking to expand its market reach into North America with its DrugSorb-ATR product, which is aimed at addressing a significant unmet need in cardiac surgery. The company is leveraging its existing international business and experience to support this expansion.

Comparison to Industry Standards

• CytoSorbents' 11% product revenue growth is a positive sign, but it is important to compare this to the growth rates of other medical device companies in the blood purification space, such as Baxter International or Fresenius Medical Care, to assess its relative performance.
• The decrease in gross margins to 61% is a concern and should be compared to the average gross margins of similar companies to determine if this is an industry-wide trend or specific to CytoSorbents.
• The company's adjusted EBITDA loss of $3.6 million is an improvement, but it is still important to compare this to the profitability of other companies in the medical device sector to assess its financial health.
• The potential market size for DrugSorb-ATR is estimated to be $300 million initially, with potential to reach $1-2 billion, which is a significant opportunity, but the company's ability to capture this market share will depend on its commercialization strategy and competitive landscape.
• The company's MDSAP certification is a positive step, but it is important to compare the time and cost of obtaining this certification to other companies in the medical device industry to assess its efficiency.

Stakeholder Impact

• Shareholders will be encouraged by the revenue growth and improved financial performance.
• Employees will be impacted by the company's growth and expansion plans.
• Customers will benefit from the potential availability of DrugSorb-ATR.
• Suppliers will be impacted by the company's production and supply chain activities.
• Creditors will be impacted by the company's financial performance and cash flow.

Next Steps

• The company will focus on the regulatory review process for DrugSorb-ATR with the FDA and Health Canada.
• The company will prepare for the potential commercial launch of DrugSorb-ATR in North America.
• The company will continue to execute on its strategy and position itself for the next stage of growth.
• The company will continue to monitor and improve its manufacturing processes to return to normalized production levels and product gross margins.

Key Dates

Keywords

CytoSorb, DrugSorb-ATR, blood purification, cardiac surgery, FDA, Health Canada, MDSAP, regulatory approval, revenue growth, net loss, EBITDA, Brilinta, ticagrelor, CABG, hemoperfusion